%0 Journal Article
%A Rieder, Marina
%A Gauchel, Nadine
%A Kaier, Klaus
%A Jakob, Carolin
%A Borgmann, Stefan
%A Classen, Annika Y
%A Schneider, Jochen
%A Eberwein, Lukas
%A Lablans, Martin
%A Rüthrich, Maria
%A Dolff, Sebastian
%A Wille, Kai
%A Haselberger, Martina
%A Heuzeroth, Hanno
%A Bode, Christoph
%A von Zur Mühlen, Constantin
%A Rieg, Siegbert
%A Duerschmied, Daniel
%T Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities.
%J Clinical research in cardiology
%V 111
%@ 1861-0692
%C Berlin
%I Springer
%M DKFZ-2021-02123
%P 322–332
%D 2022
%Z 111, pages 322–332 (2022)
%X Coagulopathy and venous thromboembolism are common findings in coronavirus disease 2019 (COVID-19) and are associated with poor outcome. Timely initiation of anticoagulation after hospital admission was shown to be beneficial. In this study we aim to examine the association of pre-existing oral anticoagulation (OAC) with outcome among a cohort of SARS-CoV-2 infected patients.We analysed the data from the large multi-national Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) from March to August 2020. Patients with SARS-CoV-2 infection were eligible for inclusion. We retrospectively analysed the association of pre-existing OAC with all-cause mortality. Secondary outcome measures included COVID-19-related mortality, recovery and composite endpoints combining death and/or thrombotic event and death and/or bleeding event. We restricted bleeding events to intracerebral bleeding in this analysis to ensure clinical relevance and to limit reporting errors. A total of 1 433 SARS-CoV-2 infected patients were analysed, while 334 patients (23.3
%K COVID-19 (Other)
%K Oral anticoagulation (Other)
%K SARS-CoV-2 (Other)
%K Thrombosis (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34546427
%2 pmc:PMC8453472
%R 10.1007/s00392-021-01939-3
%U https://inrepo02.dkfz.de/record/176881